Press Releases

16.11.2018

• Three-month exclusivity period for negotiations with ONCOLOGIE on the global assignment of lefitolimod expired without agreement • During the exclusivity period ONCOLOGIE presented new financial terms for the transaction that were vastly inferior...

12.11.2018

The biopharmaceutical company MOLOGEN AG presented two posters on its lead compound, the TLR9 agonist lefitolimod at the SITC 2018 Congress (The Society for Immunotherapy of Cancer) in Washington D.C., U.S. (07 – 11 November 2018).

08.11.2018

• Presentation of final data from IMPULSE study and update on time line for availability of top-line data from the IMPALA study • Systematic implementation of financing measures • Cash position of €12.4 million incl. completion of capital...

05.11.2018

Berlin, 05 November 2018 – An updated prediction for the expected read out time point for the phase III IMPALA trial with the lead compound lefitolimod in metastatic colorectal cancer has been conducted on the basis of more mature patient data...

22.10.2018

Berlin, 22 October 2018 – The biopharmaceutical company MOLOGEN AG presented final data from the exploratory phase II IMPULSE study at the ESMO 2018 Congress (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) in Munich, Germany (19 – 23 October 2018). The...

04.10.2018

Berlin, 04 October 2018 – The biopharmaceutical company MOLOGEN AG will present a poster at the ESMO 2018 Congress (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) in Munich, Germany (19 – 23 October 2018). The poster is featuring final data of the...

27.09.2018
MOLOGEN AG completes capital increase with gross proceeds of around €8 million

   

Displaying results 1 bis 7 von 27

Page 1

Page 2

Page 3

Page 4

next

   

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.